Business
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
POTOMAC, MD / ACCESS Newswire / September 22, 2025 /IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease.","length":368,"tagName":"p"},{"type":"text","content":"This milestone marks a significant step in advancing IGC-AD1, the Company's proprietary formulation that combines low concentrations of delta-9 tetrahydrocannabinol (THC) a naturally derived cannabinoid, with another active pharmaceutical ingredient. Preclinical and clinical evidence suggest that IGC-AD1 has a multi-modal mechanism of action, reducing agitation while also demonstrating potential disease-modifying effects through activity against beta-amyloid plaques, tau tangles and diminished mitochondrial functioning.","length":529,"tagName":"p"},{"type":"text","content":""CALMA is a multicenter, double blind, placebo controlled, randomized trial. Enrolling 50% of the target is a key achievement for the CALMA program," said Ram Mukunda, CEO of IGC Pharma. "Agitation affects up to 76% of Alzheimer's patients and remains one of the most disruptive and underserved symptoms, with current treatments carrying black box warnings or serious side effects. IGC-AD1 offers the potential for a safer, better tolerated therapy that could meaningfully improve quality of life for both patients and caregivers. With encouraging data, from our Phase 1 and from the Phase 2 interim analysis, showing reductions in agitation, we are building strong momentum toward full enrollment and remain on track with our goal of completing the trial in early 2026."","length":795,"tagName":"p"},{"type":"text","content":"In 2025, new sites were added to broaden geographic reach and enhance patient diversity, including BayCare Health System (Florida), Hamilton Health Sciences (Ontario), Butler Hospital's Memory and Aging Program (Rhode Island), Lynn Health Science Institute (Oklahoma), Island Health's Royal Jubilee Hospital (British Columbia), and SCB Research (Puerto Rico). With enrollment accelerating across this network of leading centers, IGC Pharma remains on track to complete recruitment in calendar 2026.","l...